•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

S07499 Summary:

BILL NOS07499B
 
SAME ASSAME AS A00663-B
 
SPONSORSALAZAR
 
COSPNSRMAY
 
MLTSPNSR
 
Add §111-a, Ins L
 
Requires certain manufacturers of prescription drugs to notify the drug utilization review board of the proposed increase of the wholesale acquisition cost of such prescription drugs.
Go to top    

S07499 Actions:

BILL NOS07499B
 
11/03/2021REFERRED TO RULES
01/05/2022REFERRED TO HEALTH
05/05/2022AMEND (T) AND RECOMMIT TO HEALTH
05/05/2022PRINT NUMBER 7499A
05/11/20221ST REPORT CAL.1338
05/16/20222ND REPORT CAL.
05/17/2022AMENDED 7499B
05/17/2022ADVANCED TO THIRD READING
05/24/2022PASSED SENATE
05/24/2022DELIVERED TO ASSEMBLY
05/24/2022referred to health
Go to top

S07499 Memo:

Memo not available
Go to top

S07499 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                         7499--B
            Cal. No. 1338
 
                               2021-2022 Regular Sessions
 
                    IN SENATE
 
                                    November 3, 2021
                                       ___________
 
        Introduced  by Sens. SALAZAR, MAY -- read twice and ordered printed, and
          when printed to be committed to the Committee on Rules --  recommitted
          to the Committee on Health in accordance with Senate Rule 6, sec. 8 --
          committee  discharged,  bill amended, ordered reprinted as amended and
          recommitted to said committee -- reported favorably from said  commit-
          tee,  ordered  to  first  and second report, amended on second report,
          ordered to a third reading, and to be reprinted as amended,  retaining
          its place in the order of third reading
 
        AN  ACT  to  amend  the  insurance law, in relation to requiring certain
          manufacturers of prescription drugs to notify  the  superintendant  of
          any  proposed  increase  of  the  wholesale  acquisition  cost of such
          prescription drugs
 
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
 
     1    Section  1. The insurance law is amended by adding a new section 111-a
     2  to read as follows:
     3    § 111-a. Notification of prescription drug price increases by manufac-
     4  turers. (a) This section shall apply to a manufacturer of a prescription
     5  drug that is purchased or reimbursed in this state by any of the follow-
     6  ing:
     7    (1) An insurance company authorized in this state  to  write  accident
     8  and  health  insurance,  a  company organized pursuant to article forty-
     9  three of this chapter,  a  municipal  cooperative  health  benefit  plan
    10  established  pursuant  to article forty-seven of this chapter, an organ-
    11  ization certified pursuant to article forty-four of  the  public  health
    12  law,  an  institution  of higher education certified pursuant to section
    13  one thousand one hundred twenty-four of this chapter, or  the  New  York
    14  state  health  insurance  plan established pursuant to article eleven of
    15  the civil service law; or
    16    (2) A pharmacy benefit manager, including an entity that  directly  or
    17  through an intermediary, manages the prescription drug coverage provided
    18  by  a  health insurer under a contract or policy delivered or issued for
    19  delivery in this state or a health plan subject to section three hundred
    20  sixty-four-j of the social services law, including  the  processing  and
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD05130-04-2

        S. 7499--B                          2
 
     1  payment of claims for prescription drugs, the performance of drug utili-
     2  zation  review, the processing of drug prior authorization requests, the
     3  adjudication of appeals  or  grievances  related  to  prescription  drug
     4  coverage,  contracting with network pharmacies, and controlling the cost
     5  of covered prescription drugs.
     6    (b) (1) A manufacturer of a prescription drug with a wholesale  acqui-
     7  sition  cost  of  more  than forty dollars for a course of therapy shall
     8  notify the superintendent, his or her deputy or other officer designated
     9  by the superintendent, if the increase in the wholesale acquisition cost
    10  of such prescription drug  is  more  than  ten  percent,  including  the
    11  proposed  increase and the cumulative increases that occurred within the
    12  previous twenty-four months. For purposes of this section, a "course  of
    13  therapy" is defined as either of the following:
    14    (i) the recommended daily dosage units of a prescription drug pursuant
    15  to its prescribing label as approved by the federal Food and Drug Admin-
    16  istration for thirty days; or
    17    (ii)  the recommended daily dosage units of a prescription drug pursu-
    18  ant to its prescribing label as approved by the federal  Food  and  Drug
    19  Administration for a normal course of treatment that is less than thirty
    20  days.
    21    (2)  (i) The notice required by paragraph (1) of this subsection shall
    22  be provided in writing to the superintendent at least sixty  days  prior
    23  to  the  planned  effective  date  of the increase and shall include the
    24  proposed increase and the cumulative increases that occurred within  the
    25  previous twenty-four months.
    26    (ii) The superintendent shall forthwith publish the notice required by
    27  paragraph  (a)  of  this  subdivision  on  the  department  of financial
    28  services website within five days of its receipt.
    29    (3) (i) The notice required by paragraph (1) of this subsection  shall
    30  include the date of the increase, the current wholesale acquisition cost
    31  of  the  prescription drug, and the dollar amount of the future increase
    32  in the wholesale acquisition cost of the prescription drug.
    33    (ii) The notice required by paragraph (1)  of  this  subsection  shall
    34  include  a  statement  regarding  whether a change or improvement in the
    35  drug necessitates the price increase.  If  so,  the  manufacturer  shall
    36  describe the change or improvement.
    37    (4)  Information  supplied  by a manufacturer pursuant to this section
    38  that the manufacturer has designated as a trade secret shall be  consid-
    39  ered confidential and a trade secret and shall not be disclosed directly
    40  or  indirectly  by  the  superintendent.  Notwithstanding  the foregoing
    41  sentence, the superintendent shall be permitted to disclose  information
    42  in an aggregated format if such aggregate information cannot directly or
    43  indirectly  be  used  to  identify trade secret information related to a
    44  specific manufacturer or the manufacturer's prescription drug, including
    45  but not limited to any information related to pricing for  the  manufac-
    46  turer's prescription drug that has been designated as a trade secret.
    47    (5) In the event that a manufacturer of a prescription drug subject to
    48  this  section  does not report the information required in paragraph (1)
    49  of this subsection, the  superintendent  is  authorized  to  impose  any
    50  penalty  or  remedy authorized by this chapter, after notice and a hear-
    51  ing, against such manufacturer of up to five thousand  dollars  per  day
    52  for  every day after the reporting period described in this section that
    53  the required information is not reported.
    54    § 2. This act shall take effect immediately.
Go to top